Media Doctor Canada
Follow us on Twitter








"Aromasin approved for breast cancer cases; Post-menopausal women benefit To be used after tamoxifen"

Toronto Star

Source: Toronto Star

Published: 19 May 2022

Category: Pharmaceutical

Rating: (2½ stars)

what they said (Hover the mouse cursor over underlined words for more info)

A new drug is now part of the Canadian arsenal for post- menopausal women fighting breast cancer.
Health Canada has approved the Pfizer drug Aromasin for use after surgery in post-menopausal women who have estrogen-receptor positive breast cancer and who've already had two to three years of tamoxifen therapy.
Aromasin is one of three new drugs called aromatase inhibitors, said Dr. Kathleen Pritchard of the University of Toronto and the Sunnybrook Regional Cancer Centre. Pritchard's research interests involve the role of hormones in breast cancer. She is not a paid consultant for the drug firm Pfizer Canada....

The original article can found in the Media Doctor archives.

how did it rate? (more information)

Criteria Rating
Total Score 5 of 10
Availability of Treatment Satisfactory (?)
Novelty of Treatment Satisfactory (?)
Disease Mongering Satisfactory (?)
Treatment Options Satisfactory (?)
Costs of Treatment Not Satisfactory (?)
Evidence Not Satisfactory (?)
Quantification of Benefits of Treatment Not Satisfactory (?)
Harms of Treatment Not Satisfactory (?)
Sources of Information Satisfactory (?)
Relies on Press Release Not Applicable
Quantification of Harms of Treatment Not Satisfactory (?)

what we said (Hover the mouse cursor over underlined words for more info)

A few simple additions could have significantly improved the information quality of this article. The benefit of Aromasin (exemestane) was stated in relative terms instead of absolute, which was 4.7%. There was no discussion of the strength of the evidence or the potential harms of the treatment. Although, this grading scale does not call for it, the description of the drug's mechanism of action was valuable in explaining why this drug utility is limited to post-menopausal women. The drug's availability in Canada was limited to Ontario, which is appropriate given that it is a Toronto paper.

public forum

There are currently no comments on this article.

voice your opinion in the forum

  • All comments and feedback submitted to Media Doctor are subject to editorial approval before being made viewable by the public. It may take up to a week for your comments to be approved. Additionally, no response will be given to questions posed in public comments. Media Doctor does not provide medical advice, or answers to medical questions posed by the public.
  • If you provide your email address it will not be displayed to the general public.
  • Comments may be edited by Media Doctor to remove defamatory or sensitive statements, and brand names.
  • Required fields are marked with an asterisk (*).
Name: *
Comments: *
Copyright © Media Doctor Canada